Researchers at Stanford University School of Medicine who used PET found that the tracer Cu-64-DOTA-AbOX40 yielded 95% and over 90% accuracy in identifying activated T-cells in cell cultures and mouse models with cancer, respectively, that were given a vaccine containing agents stimulating OX40 production and binding. The findings in The Journal of Clinical Investigation suggest the OX40 tracer may prompt earlier imaging and improved treatment for people with cancer, said researcher Dr. Sanjiv Gambhir.
PET tracer shows promise in evaluating cancer vaccine response
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.